Marion David
About Marion David
Marion David is a scientist specializing in immunology, preclinical pharmacology, and safety, currently working at Sangamo Therapeutics, Inc. since 2016. He has conducted significant research on the anticancer effects of Dendrogenin A, particularly in the context of acute myeloid leukemia.
Work at Sangamo Therapeutics
Marion David has been employed at Sangamo Therapeutics, Inc. since 2016, serving as a Scientist in Immunology, Preclinical Pharmacology & Safety. In this role, David is responsible for project design and management, particularly focusing on the development of Dendrogenin A. His work includes conducting animal experimentation to assess the anticancer effects of Dendrogenin A on tumorigenesis from acute myeloid leukemia (AML) cell lines, utilizing NSG mice models to monitor leukemic engraftment.
Education and Expertise
Marion David completed his PhD in Life Science, Molecular Biology, and Oncology at Université Claude Bernard Lyon 1 from 2007 to 2010. Prior to this, he earned a Bachelor's degree in Cellular Biology, Physiology, and Genetics in 2004, followed by a Master's degree in Cellular and Molecular Biology and Oncology in 2006 from the same institution. Additionally, he obtained a Degree in Animal Experimentation - level 1 in 2007. His educational background provides a solid foundation for his expertise in immunology and preclinical pharmacology.
Background in Cancer Research
Before joining Sangamo Therapeutics, Marion David held several research positions. He worked at INSERM as a Doctoral Researcher focusing on breast cancer and metastasis from 2007 to 2010. Following this, he served as a Postdoctoral Research Fellow at INSERM from 2011 to 2012, where he specialized in cancer biology and transcriptomic data analyses. He also worked at AFFICHEM from 2012 to 2015, conducting research on leukemia, autophagy, and preclinical studies.
Research Contributions
Marion David has contributed significantly to cancer research, particularly in the area of Dendrogenin A. He has been involved in the modulation of Liver X receptor and cytotoxic autophagy, which are key components of the action mechanism of Dendrogenin A. David collaborated with the Cancer Research Centre of Toulouse on the preclinical development of Dendrogenin A (DDA AF122) for the treatment of acute myeloid leukemia. He also co-authored a publication on the preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation.